Published in Chest on September 01, 2009
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One (2012) 0.92
An in vivo platform for tumor biomarker assessment. PLoS One (2011) 0.89
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis (2013) 0.87
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target. Oncotarget (2013) 0.87
Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Mol Clin Oncol (2013) 0.86
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer (2012) 0.84
Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther (2014) 0.83
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc (2014) 0.82
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Exp Ther Med (2010) 0.81
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol (2016) 0.79
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. J Cell Mol Med (2013) 0.79
Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases. Int J Oncol (2012) 0.79
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci (2016) 0.79
MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int (2015) 0.78
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study. Cancer Sci (2015) 0.77
Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res (2013) 0.77
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. Int J Clin Oncol (2012) 0.76
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. BMC Cancer (2015) 0.76
Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma. EXCLI J (2014) 0.75
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives. Respir Res (2017) 0.75
Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell. Int J Biol Sci (2016) 0.75
Mesothelioma - Update on Diagnostic Strategies. Clin Pulm Med (2012) 0.75
Unusual presentation and location pleural malignant mesothelioma. BMJ Case Rep (2013) 0.75
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer (2015) 0.75
Novel systemic therapy against malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget (2017) 0.75
Malignant pleural mesothelioma. J Clin Oncol (2009) 2.16
Update on malignant pleural mesothelioma. Semin Respir Crit Care Med (2011) 1.30
Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol (2012) 1.26
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol (2002) 1.21
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer (2012) 1.03
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol (2010) 1.02
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer (2011) 0.92
Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am (2005) 0.86
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res (2012) 0.83
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg (2007) 0.83
Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep (2005) 0.77